Q-omics provides the consensus-scored FAM71C profile across patient tissues and cancer cell-line models. FAM71C expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM71C is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, FAM71C RNA expression shows 11,788 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, BRCA, and LUAD as cancer lineages where FAM71C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM71C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM71C survival associations across molecular data types. FAM71C RNA expression shows survival associations in the most cancer types (15), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM71C RNA expression–survival associations across cancer types. High FAM71C expression shows unfavorable associations in HNSC, LUSC, UCEC, LIHC and THYM, but favorable associations in LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM71C RNA expression.
This table summarizes FAM71C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM71C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM71C shows lower tumor expression in THCA and READ and higher tumor expression in BRCA, KIRP and KIRC. The BRCA box plot shows higher FAM71C RNA expression in tumor versus normal tissue (log2 FC = +0.139, t-test p = .017).
This table shows molecular features associated with FAM71C in patient tissues and cancer cell lines. In patient samples, FAM71C shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM71C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
